News
RFL
1.070
-3.60%
-0.040
Rafael Holdings, Inc. Submits NDA for Remibetadex Following Phase 3 TransportNPC Study
NASDAQ · 6d ago
Weekly Report: what happened at RFL last week (1102-1106)?
Weekly Report · 6d ago
Weekly Report: what happened at RFL last week (1026-1030)?
Weekly Report · 11/02 09:47
Rafael Holdings Announces NDA Submission for Remibetadex and Reports Fiscal Year 2026 Financial Results
NASDAQ · 10/29 21:01
Rafael Holdings submits New Drug Application to FDA for remibetadex
TipRanks · 10/29 13:17
Rafael Holdings Submits NDA for Lead Rare Disease Drug
TipRanks · 10/29 12:50
Rafael Holdings GAAP EPS of -$0.18, revenue of $0.24M
Seeking Alpha · 10/29 12:13
Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY
Benzinga · 10/29 12:13
Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C
Benzinga · 10/29 12:12
Press Release: Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Dow Jones · 10/29 12:00
Press Release: Rafael Holdings Reports Fourth -2-
Dow Jones · 10/29 12:00
Weekly Report: what happened at RFL last week (1019-1023)?
Weekly Report · 10/26 09:47
Weekly Report: what happened at RFL last week (1012-1016)?
Weekly Report · 10/19 09:47
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal
Seeking Alpha · 10/15 12:30
Weekly Report: what happened at RFL last week (1005-1009)?
Weekly Report · 10/12 09:50
Weekly Report: what happened at RFL last week (0928-1002)?
Weekly Report · 10/05 09:50
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
NASDAQ · 10/04 06:01
Rafael Holdings: A Coin Flip With A Second Binary Attached - Hold
Seeking Alpha · 10/01 11:29
We're Keeping An Eye On Rafael Holdings' (NYSE:RFL) Cash Burn Rate
Simply Wall St · 10/01 10:51
Why Is Rafael Stock Falling Wednesday?
Benzinga · 09/30 17:39
More
Webull provides a variety of real-time RFL stock news. You can receive the latest news about Rafael Holdings through multiple platforms. This information may help you make smarter investment decisions.
About RFL
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. The Company's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.